HC Wainwright Issues Pessimistic Estimate for DRTS Earnings

Alpha Tau Medical Ltd. (NASDAQ:DRTS) – HC Wainwright reduced their Q3 2026 earnings per share (EPS) estimates for shares of Alpha Tau Medical in a research note issued on Tuesday, August 11th. HC Wainwright analyst Y. Chen now anticipates that the company will earn ($0.15) per share for the quarter, down from their prior estimate of ($0.14). HC Wainwright has a “Buy” rating and a $16.00 price target on the stock. The consensus estimate for Alpha Tau Medical’s current full-year earnings is ($0.67) per share. HC Wainwright also issued estimates for Alpha Tau Medical’s Q4 2026 earnings at ($0.15) EPS, FY2026 earnings at ($1.05) EPS, Q1 2027 earnings at ($0.15) EPS, Q2 2027 earnings at ($0.15) EPS, Q3 2027 earnings at ($0.15) EPS, Q4 2027 earnings at ($0.15) EPS and FY2027 earnings at ($0.60) EPS.

Alpha Tau Medical (NASDAQ:DRTS) last announced its earnings results on Monday, August 10th. The company reported ($0.50) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.36). The firm had revenue of $0.10 million for the quarter, compared to the consensus estimate of $0.14 million.

DRTS has been the topic of a number of other reports. Benchmark reiterated a “buy” rating on shares of Alpha Tau Medical in a research note on Thursday, July 23rd. LADENBURG THALM/SH SH boosted their target price on Alpha Tau Medical from $12.00 to $14.00 and gave the company a “buy” rating in a research note on Tuesday, May 12th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Alpha Tau Medical in a research note on Friday, July 17th. Barclays boosted their price objective on Alpha Tau Medical from $15.00 to $17.00 and gave the company an “overweight” rating in a research note on Thursday, June 4th. Finally, Zacks Research upgraded shares of Alpha Tau Medical from a “strong sell” rating to a “hold” rating in a research report on Monday, August 3rd. Five analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $12.80.

Alpha Tau Medical Stock Down 2.8%

Shares of NASDAQ:DRTS opened at $13.87 on Thursday. The business has a fifty day moving average price of $11.75 and a two-hundred day moving average price of $9.27. The company has a debt-to-equity ratio of 0.09, a current ratio of 7.79 and a quick ratio of 7.79. The company has a market capitalization of $1.25 billion, a PE ratio of -13.34 and a beta of 1.17. Alpha Tau Medical has a 1 year low of $3.00 and a 1 year high of $14.40.

Institutional Trading of Alpha Tau Medical

A number of large investors have recently modified their holdings of the business. Trifecta Capital Advisors LLC bought a new position in shares of Alpha Tau Medical in the 4th quarter worth $48,000. Envestnet Asset Management Inc. bought a new position in Alpha Tau Medical in the third quarter valued at $62,000. Bank of America Corp DE raised its position in Alpha Tau Medical by 2,779.1% during the third quarter. Bank of America Corp DE now owns 22,457 shares of the company’s stock valued at $101,000 after purchasing an additional 21,677 shares in the last quarter. Wells Fargo & Company MN lifted its stake in Alpha Tau Medical by 291.7% during the fourth quarter. Wells Fargo & Company MN now owns 23,500 shares of the company’s stock worth $116,000 after purchasing an additional 17,500 shares during the last quarter. Finally, Everhart Financial Group Inc. purchased a new position in shares of Alpha Tau Medical in the 2nd quarter worth about $126,000. Institutional investors own 2.65% of the company’s stock.

Insider Activity

In related news, CFO Raphi Levy sold 17,730 shares of Alpha Tau Medical stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $14.00, for a total transaction of $248,220.00. Following the completion of the sale, the chief financial officer owned 90,180 shares of the company’s stock, valued at approximately $1,262,520. This trade represents a 16.43% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 130,000 shares of company stock valued at $1,519,143 in the last quarter. Company insiders own 39.50% of the company’s stock.

About Alpha Tau Medical

Alpha Tau Medical Ltd. is a medical technology company headquartered in Ness Ziona, Israel, focused on developing targeted alpha-radiation therapies for the treatment of solid tumors. The company’s core innovation, known as Diffusing Alpha-emitters Radiation Therapy (DaRT), employs short-lived radioactive isotopes to deliver high-energy alpha particles directly within or adjacent to tumor tissues. By harnessing the potent cytotoxic effects of alpha radiation, Alpha Tau Medical aims to offer a novel approach to brachytherapy that can potentially overcome radioresistance and spare surrounding healthy tissue.

The company’s lead product, Alpha DaRT, is currently being evaluated in clinical studies for a range of indications including recurrent or metastatic head and neck cancers, skin cancers, and other solid tumors.